The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | Upcoming trends in the lung cancer treatment landscape
Liza Villaruz, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, comments on the what the future holds for the treatment of lung cancer, including an increased focus on neoadjuvant immunotherapy, as well the introduction of induction immunotherapy with chemotherapy, which has demonstrated to improve pathologic complete response (pCR) rates in patients. Further research is required to assess whether induction immunotherapy increases event-free survival (EFS) and if using immunotherapy in the induction and adjuvant settings concurrently will benefit patients. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC 2022).
